Handelsavisen
prelaunch
Companies Healthcare LINP.NS
LI
LINP.NS NSE (India) Pharmaceuticals

Linp.Ns

$669,55
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,28 %
Op margin
14,2 %
ROE
12,3 %
Net margin
13,2 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.

Business. LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
12,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LINP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LINP.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    LINP.NS maintains a strong liquidity position, with a current ratio of 4.71, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The company also has no long-term debt, which further supports its liquidity profile and reduces financial risk. Free cash flow stands at INR 723.96 million, reflecting the company's ability to generate cash after capital expenditures.

    In terms of profitability, LINP.NS reports a return on equity (ROE) of 12.26% and a return on assets (ROA) of 10.33%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that the company is generating solid returns for its shareholders and effectively utilizing its asset base to drive earnings. Gross profit of INR 3.19 billion and operating income of INR 886.30 million further support the company's profitability.

    The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the data does not specify revenue by region, but the company is likely focused on the Indian market given the currency and ticker listing. This concentration may expose the company to regional economic and regulatory risks.

    LINP.NS has demonstrated consistent revenue growth, with a total revenue of INR 6.23 billion in the latest reporting period. While no prior period data is provided to calculate a year-over-year growth rate, the company's strong operating cash flow of INR 930.16 million and free cash flow of INR 723.96 million suggest a stable and growing business. The company's capital expenditures of INR 192.44 million indicate ongoing investment in its operations.

    The risk assessment for LINP.NS indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 suggests a conservative capital structure with no long-term debt obligations. Additionally, the absence of dilution risk and the low probability of near-term equity issuance support the company's financial stability.

    Recent events and disclosures for LINP.NS do not include any material changes or significant risks that would impact the company's operations or financial position. Analysts have assigned a mean recommendation of 2.00, indicating a generally positive outlook, with one "buy" rating and no "sell" or "strong sell" ratings. The company's last actual EPS was INR 41.11, and its revenue of INR 6.23 billion aligns with its strong financial performance.

    Key takeaways
    • LINP.NS has a strong liquidity position with a current ratio of 4.71 and no long-term debt.
    • The company generates solid returns, with a ROE of 12.26% and ROA of 10.33%.
    • LINP.NS has a conservative capital structure and low liquidity and dilution risk.
    • The company's revenue is concentrated in a single segment and likely focused on the Indian market.
    • Analysts have a generally positive outlook, with one "buy" rating and no "sell" ratings.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $669,55
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $6.72B
    Net cash
    Current ratio
    4.7
    Debt / equity
    0.0
    ROA
    10.3%
    ROE
    12.3%
    Cash conversion
    113.0%
    CapEx / revenue
    -3.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin14,2 %Above median
    Net Margin13,2 %Above P75
    ROE12,3 %Above P75
    Capex / Rev-3,1 %Above median
    D/E0,00Above P75
    Cash Conv1,13Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • LINP.NS Market data — financials · 2026-05-28
    • Lincoln Pharmaceuticals Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LINP.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage